Agomelatine is a potent MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The purpose of this study was to show the convulsion-reducing effect of agomelatine, in both clinical and electrophysiological terms, in a pentylenetetrazole (PTZ)-induced experimental epilepsy model in rats.
The anticonvulsant activity of agomelatine (25 and 50 mg/kg) was evaluated in rat models of PTZ (35 and 70 mg/kg) and compared with the control groups.
Agomelatine administration at doses of 25 and 50 mg/kg resulted in a statistically significant decrease in convulsion scores and time to onset of myoclonic jerks compared to the control groups. In addition, comparison of the two doses employed showed that high-dose agomelatine (50 mg/kg) was significantly more effective than the lower dose. In addition to previous studies, we investigated the anticonvulsant effect of agomelatine using electroencephalogram (EEG). Administration of agomelatine at doses of 25 and 50 mg/kg in PTZ-induced seizures caused a significant decrease in the percentage of peak at EEG.
Our results suggest that agomelatine has anticonvulsant activity shown in PTZ-induced seizure model. The results also give some evidences that agomelatine can use on epileptic seizures, but more studies are needed.
Aguiar, C. C., Almeida, A. B., Araújo, P. V., Vasconcelos, G. S., Chaves, E. M., do Vale, O. C., Macêdo, D. S., de Sousa, F. C., Viana, G. S., Vasconcelos, S. M. (2012) Anticonvulsant effects of agomelatine in mice. Epilepsy Behav. 24, 324–328.
Boulle, F., Velthuis, H., Koedam, K., Steinbusch, H. W., van den Hove, D. L., Kenis, G., Gabriel, C., Mocaer, E., Franc, B., Rognan, D., Mongeau, R., Lanfumey, L. (2016) Behavioral and neurochemical characterization of TrkB-dependent mechanisms of agomelatine in glucocorticoid receptor-impaired mice. Eur. Neuropsychopharmacol. 26, 65–77.
Brodie, M. J., Ditcher, M. A. (1996) Antiepileptic drugs. N. Engl. J. Med. 334, 1583–1590.
Comai, S., Gobbi, G. (2014) Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J. Psychiatry Neurosci. 39, 6–21.
Dastgheib, M., Moezi, L. (2014) Acute and chronic effects of agomelatine on intravenous penthylenentetrazol-induced seizure in mice and the probable role of nitric oxide. Eur. J. Pharmacol. 736, 10–15.
Durlach-Misteli, C., Van Ree, J. M. (1992) Dopamine and melatonin in the nucleus accumbens may be implicated in the mode of action of antidepressant drugs. Eur. J. Pharmacol. 217, 15–21.
Erbas, O., Solmaz, V., Aksoy, D. (2015) Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures. Neurol. Res. 37, 1096–1101.
Hauser, W. A., Annegers, J. F., Kurland, L. T. (1993) Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 34, 453–68.
Karamustafalıoglu, O., Baran, E. (2012) Agomelatin ve etki mekanizması [Agomelatine and mode of action]. J. Mood Disord. 2, 6–13.
Mairesse, J., Silletti, V., Laloux, C., Zuena, A. R., Giovine, A., Consolazione, M., van Camp, G., Malagodi, M., Gaetani, S., Cianci, S., Catalani, A., Mennuni, G., Mazzetta, A., van Reeth, O., Gabriel, C., Mocaër, E., Nicoletti, F., Morley-Fletcher, S., Maccari, S. (2013). Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. Int. J. Neuropsychopharmacol. 16, 323–338.
Moezi, L., Shafaroodi, H., Hojati, A., Dehpour, A. R. (2011). The interaction of melatonin andagmatine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Behav. 22, 200–206.
Morley-Fletcher, S., Mairesse, J., Soumier, A., Banasr, M., Fagioli, F., Gabriel, C., Mocaer, E., Daszuta, A., McEwen, B., Nicoletti, F., Maccari, S. (2011) Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology (Berl) 217, 301–313.
Olsen, R. W., Bergman, M. O., Van Ness, P. C., Lummis, S. C., Watkins, A. E., Napias, C., Greenlee, D. V. (1981) Gamma-aminobutyric acid receptor binding in mammalian brain. Heterogeneity of binding sites. Mol. Pharmacol. 19, 217–227.
Rainer, Q., Xia, L., Guilloux, J. P., Gabriel, C., Mocaër, E., Hen, R., Enhamre, E., Gardier, A. M., David, D. J. (2012) Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int. J. Neuropsychopharmacol. 15, 321–335.
Strine, T. W., Kobau, R., Chapman, D. P., Thurman, D. J., Price, P., Balluz, L. S. (2005) Psychological distress, comorbidities and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 46, 1133–1139.
Tchekalarova, J., Atanasova, D., Nenchovska, Z., Atanasova, M., Kortenska, L., Gesheva, R., Lazarov, N. (2017) Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy. Neurobiol. Dis. 104, 1–14.
Tchekalarova, J., Nenchovska, Z., Atanasova, D., Lazarov, N., Kortenska, L., Stefanova, M., Alova, L., Atanasova, M. (2016) Long-term consequences of prophylactic treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. Behav. Brain Res. 302, 11–28.
Uzbay, I. T. (2012) Agomelatin: Genel bilgiler, farmakolojisi ve kullanım güvenliği [Agomelatine: General information, pharmacology and safety of use]. Klinik Psikiyatri 15, 9–19.
Velisek, L. (2016). Models of chemically-induced acute seizures. In: Pitkänen, A., Schwartzkroin, P. A., Moshé, S. L. (eds.) Models of Seizures and Epilepsy. Elsevier, St. Louis, MI, pp. 127–152.
Vimala, P. V., Bhutada, P. S., Patel, F. R. (2014) Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med. Hypotheses 82, 105–110.